Navigation Links
Promising compound restores memory loss and reverses symptoms of Alzheimer's
Date:1/2/2013

A new ray of hope has broken through the clouded outcomes associated with Alzheimer's disease. A new research report published in January 2013 print issue of the FASEB Journal by scientists from the National Institutes of Health shows that when a molecule called TFP5 is injected into mice with disease that is the equivalent of human Alzheimer's, symptoms are reversed and memory is restoredwithout obvious toxic side effects.

"We hope that clinical trial studies in AD patients should yield an extended and a better quality of life as observed in mice upon TFP5 treatment," said Harish C. Pant, Ph.D., a senior researcher involved in the work from the Laboratory of Neurochemistry at the National Institute of Neurological Disorders at Stroke at the National Institutes of Health in Bethesda, MD. "Therefore, we suggest that TFP5 should be an effective therapeutic compound."

To make this discovery, Pant and colleagues used mice with a disease considered the equivalent of Alzheimer's. One set of these mice were injected with the small molecule TFP5, while the other was injected with saline as placebo. The mice, after a series of intraperitoneal injections of TFP5, displayed a substantial reduction in the various disease symptoms along with restoration of memory loss. In addition, the mice receiving TFP5 injections experienced no weight loss, neurological stress (anxiety) or signs of toxicity. The disease in the placebo mice, however, progressed normally as expected. TFP5 was derived from the regulator of a key brain enzyme, called Cdk5. The over activation of Cdk5 is implicated in the formation of plaques and tangles, the major hallmark of Alzheimer's disease.

"The next step is to find out if this molecule can have the same effects in people, and if not, to find out which molecule will," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "Now that we know that w
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Stanford geoscientist cites critical need for basic research to unleash promising energy sources
2. Alzheimers disease in mice alleviated promising therapeutic approach for humans
3. Stem cells + nanofibers = Promising nerve research
4. Berkeley Lab scientists help develop promising therapy for Huntingtons disease
5. Promising new drug target for inflammatory lung diseases
6. Space research institute awards funding to promising medical products
7. American Health Assistance Foundation announces grants to advance promising vision research
8. 22 of Americas most promising scientists selected as Pew Biomedical Scholars
9. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
10. Ultrasensitive biosensor promising for medical diagnostics
11. Promising developments in early diagnosis and treatment of mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... Researchers at the Institute of Neurosciences at Universitat ... by the Nurr1 gene in neuron survival associated with ... of Biological Chemistry , allows scientists to study a ... between alterations in neural connections, which are known to ...
... to date, a team of more than 200 scientists from ... boost or sabotage the brain,s resistance to a variety of ... advance online edition of Nature Genetics , the study ... brain size and intelligence. "We searched for two ...
... co-led by UC Davis neurologist Charles DeCarli and conducted by ... 71 institutions in eight countries, has advanced understanding of the ... studies appear in the April 15 edition of the journal ... on a genetic analysis of more than 9,000 people, has ...
Cached Biology News:Researchers have identified a gene with a key role in neuronal survival 2International team uncovers new genes that shape brain size, intelligence 2International team uncovers new genes that shape brain size, intelligence 3Large international study finds memory in adults impacted by versions of 4 genes 2Large international study finds memory in adults impacted by versions of 4 genes 3Large international study finds memory in adults impacted by versions of 4 genes 4
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... SAN DIEGO and HONG KONG ... an innovative rare disease therapeutics enterprise, announced today that ... joined the company as vice president, research. Dr. McKew ... research, including key leadership positions at the National Institutes ... to its acquisition by Wyeth). Dr. McKew will lead aTyr,s ...
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... ,, BEIJING , June 27, 2010 , ... - Outstanding Young Women Biologists, Chemists, Physicists ... , ... from Africa , the Middle East , Asia , Latin America ...
... , June 26, 2010 Amylin Pharmaceuticals, ... an analysis of an integrated database of clinical studies ... associated with SYMLIN® (pramlintide acetate) injection use compared to ... rapid-acting insulin. These findings were presented at the 70th ...
... , June 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE,Amex: ... with operations in the U.S. and China , announced ... accredited,investors (the "Investors") to sell in a registered direct offering ... million . Each unit was,priced at $2.15 and ...
Cached Biology Technology:Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 2Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 3Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 4Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 5Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 6Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards 7Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 2Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 3Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 4Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 5Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 6Meta-Analysis of SYMLIN(R) Clinical Data Showed No Increased Risk of Cardiovascular Adverse Events Associated With SYMLIN Treatment in Patients With Type 2 Diabetes 7NeoStem Raises $5 Million in Registered Direct Offering 2NeoStem Raises $5 Million in Registered Direct Offering 3NeoStem Raises $5 Million in Registered Direct Offering 4
... XIII in both reduced and non-reduced forms. It ... or human Factor XII. Factor XIII is a ... two subunits. Factor XIII-A is the catalytic subunit ... XIII is present in plasma as an Alpha2Beta2 ...
Anti-CaM kinase II recognizes the enzymes a subunit (6) and reacts with tissue from all mammalian species tested, as well as with chicken and frog tissues....
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Goat polyclonal to Centaurin alpha 2**...
Biology Products: